Navamedic ASA (0FDB.L)
| Previous close | 37.20 |
| Open | 0.00 |
| Bid | N/A x N/A |
| Ask | N/A x N/A |
| Day's range | 0.00 - 0.00 |
| 52-week range | |
| Volume | |
| Avg. volume | 134 |
| Market cap | N/A |
| Beta (5Y monthly) | 0.28 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
PR NewswireNavamedic ASA: Invitation to 2024 1st quarter presentation
Navamedic ASA (OSE: Nava) will be presenting its 1st quarter 2024 results on Tuesday, April 30, 2024. The presentation will be held at Haakon VIIs gate 2 in Oslo and the event will start at 08.30 CET. A link to the webcast and the presentation will be available through the Navamedic web site on the following link: https://navamedic.com/investors/financial-results/
PR NewswireNavamedic welcomes new shareholders
Navamedic (OSE: NAVA) is pleased to welcome new shareholders and delighted to see existing shareholders acquire a bigger stake following Ingerø Reiten Investment Company's (IRIC) sale of its entire 17.1 percent interest in the company.
PR NewswireNavamedic ASA: Notification of major shareholding and mandatory notification of trade
Ingerø Reiten Investment Company AS ("IRIC") has today sold all of its shares in the Nordic pharmaceutical company Navamedic ASA. The shares were sold for 32 kroner per share, for total gross proceeds of approximately NOK 95 million, or about 2.7 times the amount invested. IRIC has been Navamedic's principal owner and strategic partner since 2019. IRIC will use part of the proceeds to strengthen its balance sheet by paying off debt.
